Over the past several years, cancer immunotherapy has made extraordinary progress both conceptually and in clinical practice. The recent FDA approval of drugs in this area has paved the way for many upcoming independent and combination therapies in the immuno-oncology segment.
A variety of strategies are continuing to evolve in the laboratory and in the clinic, including cancer vaccines, T cells, and immune checkpoint blockade. Despite their promise, much more research is needed to understand how and why certain cancers fail to respond to immunotherapy and to predict which therapeutic strategies, or combinations thereof, are most appropriate for each patient.
The Cancer Immunotherapy Congress held on 19 - 20 May 2016 in Boston, USA presented these ongoing challenges along with some recent technological advances.
• Cellular Immunotherapy
• Predictive Biomarkers for response
• Combinational Therapy and Toxicity
• New Immunotherapy Targets
• Pre-clinical & Translational
• Moving Beyond Current Vaccines
0 DAY EVENT
0 Hours of Networking
The Cancer Immunotherapy Congress
Four Points Sheraton Wakefield Boston
1 Audubon Road
Our block of rooms at the Four Points Sheraton Wakefield Boston has now expired. You may still be able to book accommodation at the Four Points Sheraton Wakefield Boston by visiting their website directly - http://www.starwoodhotels.com/fourpoints/property/overview/index.html?propertyID=232/ Alternatively, you can see a list of nearby hotels by clicking here.(Please note that we do not authorise any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than me regarding your accommodation requirements for this event, please let me know immediately)